21.2 C
Vientiane
Monday, October 27, 2025
spot_img
Home Blog Page 33

Phoenix Aviation Capital and AIP Capital Announce Upsize of Senior Secured Credit Facility to $550 Million

DUBLIN and STAMFORD, Conn. and NEW YORK, Oct. 23, 2025 /PRNewswire/ — Phoenix Aviation Capital (“Phoenix” or “the Company”), a full-service aircraft lessor managed by AIP Capital (“AIP”), an alternative investment manager focused on opportunities in asset-based finance and a portfolio company of funds advised or controlled by affiliates of BC Partners Advisors L.P., announced a $250 million upsize to its $300 million senior secured credit facility (“the facility”), bringing total commitments to the facility to $550 million.

HSBC, Truist, Fifth Third Bank, Crédit Agricole, BNP Paribas and Bayern LB participated in this upsize to the facility. Royal Bank of Canada (“RBC”) acted as Structuring Agent with RBC, Citibank and Morgan Stanley acting as Joint Lead Arrangers. Since the beginning of 2025, Phoenix has raised over $2 billion in bank and institutional capital to support its growth strategy.

“This expanded participation in the facility represents further confidence in the business among Phoenix’s lender group,” said Jared Ailstock, Managing Partner at AIP. “We are grateful for the support from the bank group as we continue to execute on Phoenix’s growth strategy.”

“Welcoming new lenders demonstrates the support Phoenix and AIP have in the aviation bank market,” said Patrick Schafer, Partner at BC Partners and board member of Phoenix. “The facility will provide Phoenix with additional capacity and flexibility to support the Company’s global airline customers.”

Vedder Price served as transaction counsel and PwC acted as tax advisor to Phoenix and AIP. McCann Fitzgerald also acted in capacity as Irish counsel to Phoenix and AIP. Clifford Chance served as transaction counsel to the lenders.

About AIP Capital
AIP Capital (AIP) is a global alternative investment manager focused on opportunities in asset-based finance including aviation and equipment finance. AIP, together with its affiliates, manages approximately $4 billion of assets on behalf of a diversified global investor base. The AIP team is comprised of more than 50 experienced professionals across AIP’s offices in Stamford, New York City, Dublin, and Singapore. For more information about AIP Capital or to speak with company executives, please contact investor.relations@aipcapital.com.

About BC Partners & BC Partners Credit
BC Partners is a leading international investment firm in private equity, private debt, and real estate strategies. BC Partners Credit was launched in February 2017, with a focus on identifying attractive credit opportunities in any market environment, often in complex market segments. The platform leverages the broader firm’s deep industry and operating resources to provide flexible financing solutions to middle-market companies across Business Services, Industrials, Healthcare and other select sectors. For further information, visit www.bcpartners.com/credit-strategy.

Media Contacts

AIP Capital Geoffrey Bayers
investor.relations@aipcapital.com

BC Partners
Luke Charalambous
Luke.Charalambous@BCPartners.com
+44 7775 180 721

 

Nature Wood Group Limited Announces Change in Controlling Shareholder Following Completion of Private Share Transfer

MACAU, Oct. 23, 2025 /PRNewswire/ — Nature Wood Group Limited (Nasdaq: NWGL) (“Nature Wood” or the “Company“), a global leading vertically-integrated forestry company headquartered in Macau, today announced a change in its controlling shareholder following the closing of a private transaction.

On October 22, 2025, the board of directors of the Company was notified that Mr. SE Hok Pan, Easy Bliss Limited, Linking Stars Limited, More Choice Global Limited, Mr. CHAN Wing Luk and Mr. HUANG Qing Cai (collectively, the “Sellers“) completed the transfer of an aggregate of 114,974,179 ordinary shares, representing approximately 86.82% of the Company’s issued and outstanding ordinary shares, to TUTU Business Services Limited, Ms. LIANG Yanxia, Mr. LI Xianfeng, Ms. MIAO Huiping, Mr. WANG Lei and Mr. WANG Gang (collectively, the “Purchasers“), pursuant to a share purchase agreement dated October 22, 2025. The closing occurred immediately upon execution of the Share Purchase Agreement.

This transaction was effected by private sale of existing ordinary shares. The Company did not issue any new shares and was not a party to the Share Purchase Agreement. Following closing, TUTU Business Services Limited became the controlling shareholder of Nature Wood Group Limited.

About Nature Wood Group Limited

Nature Wood Group Limited is a global leading vertically-integrated forestry company that focuses on timber and wood products industry. The Company’s operations cover both up-stream forest management and down-stream wood-processing and distribution. Nature Wood offers a broad line of products, including logs, decking, flooring, sawn timber, primarily through its sales network in Europe, South Asia, South America, North America and China. The Company is one of the largest exporters of wood products in Peru. For more information, please visit: www.nature-wood.com

Charming Medical Limited Announces Closing of Initial Public Offering

HONG KONG, Oct. 23, 2025 /PRNewswire/ — Charming Medical Limited (Nasdaq: MCTA) (the “Company”), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”) at a price of $4.00 per share (the “Public Offering Price”). The Company’s Class A Ordinary Shares began trading on the Nasdaq Capital Market under the symbol “MCTA” on October 21, 2025.

The Company received total gross proceeds of $6.4 million from the Offering, before deducting underwriting discounts, non-accountable expense allowance, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for expanding its business and geographic coverage, potential strategic investments and acquisitions, research and development, and for general working capital and corporate purposes.

The Company has granted the underwriters an over-allotment option to purchase up to an additional 240,000 Class A Ordinary Shares at the Public Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering (the “Over-allotment Option”), exercisable within 45 days from the closing date of the Offering. If the Over-allotment Option is exercised in full, the gross proceeds will amount to approximately $7.36 million, before deducting underwriting discounts and other offering expenses.

The Offering was conducted on a firm commitment basis. Cathay Securities, Inc. acted as the representative of the underwriters for the Offering. Ortoli Rosenstadt LLP, Harney Westwood & Riegels, and Fairbairn Catley Low & Kong acted as United States, British Virgin Islands, and Hong Kong counsels to the Company, respectively. Kaufman & Canoles, P.C. acted as U.S. counsel to the underwriters for the Offering.

The Offering was conducted pursuant to the Company’s registration statement on Form F-1 (File No. 333-287258), as amended, previously filed with, and subsequently declared effective by the United States Securities and Exchange Commission (the “SEC”) on September 30, 2025. A final prospectus describing the terms of the Offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. The Offering was made only by means of a prospectus, forming a part of the effective registration statement. Alternatively, electronic copies of the prospectus relating to the Offering may be obtained from Cathay Securities, Inc., by standard mail to 40 Wall St., Suite 3600, New York, NY 10005, United States, Attention: Shell Li, or via email at service@cathaysecurities.com, or telephone at +1 (855) 939-3888.

Before investing, investors should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Charming Medical Limited (Nasdaq: MCTA)

Charming Medical Limited (the “Company”) is a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. The Company integrates TCM principles with modern technology to enhance quality of life and promote holistic well-being. Through its four wellness centers in Hong Kong, the Company offers a wide range of services, including womb-warming therapy, pelvic detox therapy, moxibustion, prenatal massage, and traditional abdominal binding, designed to address women’s health issues such as menstrual irregularities, hormonal imbalance, and postpartum recovery. Under its “Beauty Lab” brand, Charming Medical Limited also develops and distributes TCM-inspired supplements and beauty products, such as uterine care patches, probiotic washes, and nourishing herbal formulations, aimed at improving women’s constitution and vitality. In addition, the Company provides technical training, dietary therapy consultancy, and franchise opportunities to extend its wellness philosophy to other practitioners and entrepreneurs. For more information, please visit https://charmingmed.com.

Forward-Looking Statement

Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company’s statements regarding the exercise of the over-allotment option and the Company’s intended use of proceeds from the sale of the Company’s Class A Ordinary Shares in the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

SynbioTech Brings Taiwan’s Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging

LAS VEGAS, Oct. 23, 2025 /PRNewswire/ — In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company from Taiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which will be featured at SupplySide Global 2025 from October 27–30 (Booth #6253F), has shown measurable benefits on muscle strength, endurance, and balance—offering a new microbiome-based approach to healthy aging and active living.

SynbioTech will feature its flagship probiotic TWK10® at SupplySide Global 2025, highlighting its clinically proven role in muscle health and active aging.
SynbioTech will feature its flagship probiotic TWK10® at SupplySide Global 2025, highlighting its clinically proven role in muscle health and active aging.

Backed by over a decade of research, TWK10® has been evaluated in peer-reviewed human clinical studies, demonstrating proven benefits in both active individuals and older adults. Clinical findings show that TWK10 boosts endurance performance by 20-40% and increases muscle mass by 0.5-1 kg, while improving overall strength, recovery, and mobility across life stages. One of these landmark studies was recognized by Wiley as a “Top Cited Article,” underscoring TWK10®’s scientific impact and its growing influence in gut–muscle axis research.

TWK10® has earned strong credibility and recognition across global regulatory frameworks, including U.S. GRAS Self-Affirmed status, Korea’s Health Functional Food approval, Taiwan’s Health Food certification with an anti-fatigue claim, Malaysia’s MAL registration, and Thailand’s probiotic listing.

The recent Japan FFC authorization marks another milestone, positioning TWK10® among the most clinically and regulatorily validated probiotics for muscle health worldwide. Together with a growing portfolio of real-world data, these achievements reinforce SynbioTech’s reputation as a science-driven innovator delivering microbiome-based health solutions through probiotics and postbiotics.

“For SynbioTech, it’s more than a product story—it’s about proving how microbiome science can truly enhance daily life,” said Chuan-Hsien Yang, Chief Operating Officer at SynbioTech. “TWK10® is the result of years of research that bridge traditional fermentation knowledge from Taiwan with modern clinical science.”

SynbioTech continues to expand its global partnerships and research collaborations, reflecting a broader vision to connect Asian innovation with global health markets and empower people to live healthier through microbiome science.

About Synbio Tech Inc.
Founded in 2000, Synbio Tech is a global biotechnology company specializing in probiotics, postbiotics, and microbiome-based health solutions. With over 25 years of R&D experience and a fully integrated CDMO platform, the company partners with more than 600 brands across 35 countries to deliver “From Strain to Solution” innovations that change lives with probiotics.
www.synbiotech.com

Retro Stage Unveils 2025 Vintage “Happy Halloween” Collection

MONTEREY, Calif., Oct. 23, 2025 /PRNewswire/ — Vintage-inspired clothing brand Retro Stage is gearing up for the fast-approaching freaky festivities with the reveal of their 2025 Halloween collection. The Happy Halloween line is filled to the brim with frighteningly fabulous looks, featuring pieces inspired by spooky motifs, beloved fictional characters, and of course, classic creatures.

A Nostalgic Vision of Halloween

retro-stage-vintage-halloween-collection
retro-stage-vintage-halloween-collection

Retro Stage is eager to once again share their nostalgic vision of Halloween with their audience, with many hand-picked seasonal favorites returning in addition to the dozens of brand-new designs making their debut. Perfectly blending vintage cuts and aesthetics with delightfully creepy subject matter, this collection’s offerings span all the way from the elegant 1930s to the unconventional 1980s, meaning fans of all decades can be sure to find something to their tastes.

What to Expect from the Vintage Halloween Collection

Retro Stage provided the following sneak peek of what customers can expect to see in this new and exciting collection:

Festive Favorites

From vibrant purple bats to cozy sweaters of orange and black, this collection features everything a Halloween fan needs to rep their spooky spirit all month long. Customers can express themselves with blood-spattered dresses, skull-patterned lace, fun monochrome looks, and so much more.

Punk & Goth Picks

Halloween is a time for the darker side of fashion to take the spotlight, and that’s where the punks and goths come in. Both veterans and newcomers in these iconic subcultures are welcome to shop this collection’s abundance of lacy corsets, leather, silver studs, and blood-red velvet to assemble the perfect retro stage Halloween outfits.

Movie & TV Characters

Fans of Halloween classics like Beetlejuice and The Nightmare Before Christmas are in for a treat, because this collection has all the vintage-inspired costume pieces they could ask for. What’s more, there’s plenty of other pop culture couture in store, including designs inspired by Disney princesses, the beloved Addams family, the Sanderson sisters, the Mystery Gang, and even classic horror films like Carrie — with a haunting Carrie costume that’s both elegant and terrifying.

The brand emphasized their excitement to share both new and returning creations with fans this year in the hopes of making every customer’s Halloween that much more special.

“Halloween and vintage fashion have always gone hand in hand,” said CEO when asked about the collection. “All the most classic horror and monster movies came out at the same time that the most iconic retro aesthetics were first hitting the scene. We had costumers incorporating what was popular at the time into their designs, and when those designs debuted to audiences, they went on to inspire future fashion trends and sort of set the tone for what we still see in scary movies and modern Halloween costumes.” He went on to note that while plenty of costume stores stock vintage-inspired pieces, Retro Stage’s high-quality vintage Halloween costumes & dresses can be reworn and even incorporated into other outfits once Halloween is over, firmly setting the brand apart from the average retailer.

Those interested in celebrating a vintage-style holiday are invited to check out the Happy Halloween collection on the Retro Stage website and pick out their favorite spooky seasonal pieces before time runs out to shop. Customers can also explore the Halloween Sale page for heavily discounted offerings guaranteed to ship in 8 days or less.

About Retro Stage

Retro Stage is a popular vintage fashion brand featuring classic clothing and accessories inspired by 20th-century aesthetics. As a vintage style pioneer, Retro Stage is more than a brand; it’s a way of life, helping every customer explore the history of fashion through chic and glamorous retro style. “Beauty never fades,” said the Retro Stage team. “All we want to do is encourage women to build a better life for themselves and confidently embrace their natural allure.”

ROYAL CARIBBEAN REVEALS SUMMER 2027 ADVENTURES TO ALASKA

Vacationers are in for an action-packed lineup from Anthem of the Seas and its first-ever Cruisetour experiences to more ways to explore on Quantum, Serenade and Voyager of the Seas

MIAMI, Oct. 22, 2025 /PRNewswire/ — Calling all adventure-seekers: Royal Caribbean has revealed its lineup of summer 2027 getaways for travelers to experience the wonders of Alaska. Vacationers can secure their front-row seats to The Last Frontier on weeklong voyages on Anthem, Quantum, Serenade and Voyager of the Seas. The boldest adventures on land and at sea are on deck with 7-night adventures from Seattle; Seward, Alaska; and Vancouver, British Columbia in Canada, along with ways to take exploration to the next level with multi-night Cruisetour experiences on land. The 2027 Alaska vacations are now open to book on Royal Caribbean’s website for Crown & Anchor Society loyalty members, ahead of the official opening on Thursday, Oct. 23.

Serenade of the Seas features ocean-facing glass elevators and floor-to-ceiling windows, delivering to vacationers breathtaking sights of every destination. The Radiance Class vacation also touts experiences for guests of all ages, from rock climbing to poolside movie nights under the stars, to favorite restaurants such as Chops Grille, Giovanni’s Table and Izumi.
Serenade of the Seas features ocean-facing glass elevators and floor-to-ceiling windows, delivering to vacationers breathtaking sights of every destination. The Radiance Class vacation also touts experiences for guests of all ages, from rock climbing to poolside movie nights under the stars, to favorite restaurants such as Chops Grille, Giovanni’s Table and Izumi.

From incredible landscapes to breathtaking wildlife, opportunities for exploration include whale watching in Sitka, Alaska, meeting professional dog sledders and their dog teams at Mendenhall Glacier near Juneau, Alaska, sky high views of Alaska’s wilderness on helicopter tours and more. The memorable experiences continue on board with a variety of ways to thrill, chill, dine and be entertained for all ages. With the all-glass North Star observation capsule, rock-climbing walls, SeaPlex – featuring bumper cars, a sports court and roller-skating – and more, vacationers of all ages have ways to adventure at every corner.

Alaska Summer 2027 Highlights 

  • Anthem of the Seas – From Vancouver and Seward
    Vacationers on Anthem can explore the state’s beauty on 7-night vacations from Seward and Vancouver to picturesque spots like Skagway and Ketchikan and through Hubbard Glacier. Plus, for the first time on Anthem, travelers can dial up the action before or after their adventure with a lineup of immersive overnight Cruisetour experiences on land. The expertly guided multi-night land expeditions span from exploring the must-see Denali National Park to journeys in luxury glass dome rail cars that put the sights of Alaska on full display. The memory making continues on Anthem with activities like the North Star all-glass observation capsule and the largest indoor activity space at sea with SeaPlex, along with flavors for every palate like Mediterranean-inspired dishes at Solarium Bistro, American classics at Johnny Rockets and more.
  • Quantum of the Seas – From Seattle
    After a summer Down Under in Australia, Quantum of the Seas will sail 7-night vacations from Seattle to incredible landscapes across Sitka, Juneau and Skagway, where travelers can kayak in pristine waters and spot sea otters and other wildlife along the shore. More adventures await with the fan-favorite FlowRider surf simulator, an outdoor movie screen and laser tag. When it’s time to refuel, there’s a variety of ways to dine, including family-style Tuscan favorites at Jamie’s Italian, premium steaks at Chops Grille and fresh sashimi at Izumi.
  • Serenade of the Seas – From Vancouver
    Vacationers can embark on weeklong explorations through Alaska’s Inside Passage with majestic sights at Sitka, Icy Strait Point and Ketchikan. More activities for the whole family are in store onboard with a rock-climbing wall, poolside movie nights under the stars, live music at Schooner Bar, and flavors from restaurants such as Giovanni’s Table, Chops Grille and Izumi.
  • Voyager of the Seas From Seattle
    Travelers can marvel at the natural beauty of Alaska for seven nights with visits to Juneau, Skagway, and take in the breathtaking views of Endicott Arm and Dawes Glacier. Every kind of vacationer can make memories while on Voyager with an adults-only, indoor-outdoor Solarium for some relaxation time and ice skating, a mini golf course, laser tag and more.

Vacationers can learn more about the upcoming Alaska adventures on Royal Caribbean’s website.

About Royal Caribbean
Royal Caribbean, part of Royal Caribbean Group (NYSE: RCL), has delivered memorable vacations for more than 50 years. The cruise line’s game-changing ships and exclusive destinations revolutionize vacations with innovations and an all-encompassing combination of experiences, from thrills to dining and entertainment, for every type of family and vacationer. Voted “Best Cruise Line Overall” for 22 consecutive years in the Travel Weekly Readers Choice Awards, Royal Caribbean makes memories with adventurers across more than 300 destinations in 80 countries on all seven continents, including the line’s top-rated exclusive destination, Perfect Day at CocoCay in The Bahamas.   

Media can stay up to date by following @RoyalCaribPR on X and visit www.RoyalCaribbeanPressCenter.com. For additional information or to book, vacationers can visit www.RoyalCaribbean.com, call (800) ROYAL-CARIBBEAN or contact their travel advisor.  

 

Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC

BEIJING, Oct. 22, 2025 /PRNewswire/ — In October 2025, a partnership between Biokin—a rising star in China’s innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed to be the largest antibody-drug conjugate (ADC) milestone payment among hundreds of out-licensing deals involving Chinese innovative drugs. Notably, the overall transaction had previously set a record for the total value of a single-drug asset license in China.

iza-bren, a potential first-in-class ADC comprised of an EGFR x HER3 bispecific antibody conjugated
iza-bren, a potential first-in-class ADC comprised of an EGFR x HER3 bispecific antibody conjugated

In recent years, China’s dynamic pharmaceutical ecosystem has rapidly emerged as one of the world’s leading sources of novel drug molecules. Such collaborations, however, often come with uncertainties in both China and the U.S. Following the $800 million upfront payment received in early 2024, Biokin’s partnership with BMS has advanced smoothly once again. This progress has prompted skeptics to recognize iza-bren’s blockbuster potential.

The momentum behind the collaboration stems from the continued validation of iza-bren’s efficacy. At the 2025 World Congress on Lung Cancer (WCLC), after Dr. Fang Wenfeng presented domestic clinical data, a physician from the prestigious MD Anderson Cancer Center in the U.S. approached him, expressing hope the drug would launch in the U.S. as soon as possible.

Such a conversation would have been unimaginable in the past. Despite remarkable progress of China’s biopharmaceutical industry over the past decade, nearly all first-in-class new drugs still originate from Western countries. While China has accelerated efforts to bring in overseas innovations, it has also strongly supported domestic pharmaceutical companies and clinical systems in pursuing innovation.

Dr. Fang works at the renowned Sun Yat-sen University Cancer Center (SYSUCC), where his team has conducted clinical research on iza-bren for several years. In a study of 50 patients with locally advanced or metastatic EGFR-mutated NSCLC—who had received first-line treatment with other drugs but no chemotherapy—iza-bren controlled tumor progression for over a year, nearly doubling the duration achieved by the current global standard of care.

More positive data about iza-bren emerged at the 2025 European Society for Medical Oncology (ESMO) Congress in mid-October. For the first time, results from the pivotal Phase III registration trial of this global first-in-class EGFR×HER3 bispecific ADC were reported: the drug achieved a twofold improvement in key efficacy endpoints in third-line or above treatment for nasopharyngeal carcinoma (NPC). The full study results were published in The Lancet, a leading international medical journal.

More than 40 clinical studies of iza-bren are currently underway worldwide, including 10 Phase III registration trials in China and 3 key registration studies overseas. Regulators in China and the U.S. have designated some of these studies as “Breakthrough Therapies” to expedite development. The drug is expected to launch first in China in 2026—three years earlier than its planned U.S. launch—marking a milestone moment for China’s innovative pharmaceutical sector.

Growing industry consensus on iza-bren’s blockbuster potential began at the 2023 ASCO Annual Meeting. At the time, Professor Zhang Li from SYSUCC first reported promising efficacy signals of the drug’s Phase I trial.

Iza-bren’s unique bispecific ADC technology and its ability to target two high-value antigens (EGFR and HER3) have endowed it with strong efficacy and broad applicability. This has attracted multinational pharma giants facing looming patent cliffs and eager to expand their ADC portfolios. BMS reached a global co-development and commercialization agreement with Biokin, the developer of iza-bren, at a potential total value of up to $8.4 billion.

Biokin distinguishes itself among China’s biotech companies with its unconventional approach. It transitioned from a generic drug manufacturer, and its founder, Zhu Yi, holds no medical degrees from Europe or the U.S., nor has he worked at multinational pharmaceutical companies. Over a decade ago—when the Chinese government first began mapping out the blueprint for its innovative drug ecosystem—Zhu made a firm decision to go all-in on innovative drug R&D. In 2014, amid a global downturn in drug development, he established a lean scientific team in Seattle, U.S., marking the start of his drug R&D journey. Zhu fully leveraged the strengths of both the Chinese and U.S. biopharmaceutical ecosystems: in the U.S., he accessed resources that support early-stage innovation; in China, the efficient regulatory system, large pool of engineers, and abundant patient resources enabled the rapid translation of innovative ideas into reality.

Zhu negotiated distinctive terms with BMS: beyond the substantial financial offer, he secured overseas R&D and commercialization rights. He firmly believes the latter is essential for Biokin to truly join the ranks of global pharmaceutical companies. The establishment and progress of this ambitious collaboration model have empowered Biokin to send a strong message for China’s biotech industry: to become a multinational company within five years.

Beyond iza-bren, Biokin also announced clinical trial results for T-bren, its second ADC drug in Phase III, at the ESMO Congress. Targeting common cancers such as lung, gastric, and breast cancer, T-bren also showed strong signals of becoming a best-in-class drug. Additionally, China’s CDE recently approved Biokin’s first antibody-radionuclide conjugate (ARC) drug to enter clinical trials.

Biokin’s story has captured the market’s attention. On China’s mainland stock exchanges, its market value has surged 15-fold in just over two years. Now, Hong Kong’s capital market is embracing the company. Amid the hesitation of onlookers, Biokin may well emerge as a global leader in biopharmaceuticals.

Data Zoo Partners with Ping Identity to Power PingOne Verify with Global Authoritative Data

SYDNEY, Oct. 22, 2025 /PRNewswire/ — Data Zoo, the trusted data layer for global identity verification, today announced its partnership with Ping Identity, a leader in securing digital identities for the world’s largest enterprises. The strategic relationship provides authoritative data to PingOne Verify, offering businesses a faster, frictionless, and secure way to verify identities across global markets.

Data Zoo joins a growing list of technology partners developing integrations through the Ping Identity Global Technology Partner Program. Partner solutions built on the Ping Identity Platform help organizations compete in a new digital era where user experience is increasingly important, and security cannot be sacrificed.

“Our partnership with Ping Identity advances digital trust by bringing authoritative data into the PingOne Verify platform,” said Jon Jones, Chief Revenue Officer at Data Zoo. “By continually expanding our global authoritative data network, we enable real-time, trusted insights that increase customer assurance and help PingOne Verify stay ahead of sophisticated identity fraud.”

Ping customers can now enhance identity verification through Data Zoo’s global integration, providing secure access to authoritative data from more than 60 countries. As the trusted data layer for identity verification, Data Zoo continually refines its data sources to meet evolving client needs and embeds privacy and compliance into every layer, helping enterprises accurately verify customers, prevent fraud, and deliver secure onboarding at scale.

“Ping Identity is committed to expanding our technology partner ecosystem to enhance digital customer experiences across the entire user journey,” said Loren Russon, Senior Vice President of Product & Technology at Ping Identity. “Our collaboration with Data Zoo makes it seamless for our customers to add unique and multi-faceted data sets to the Ping Identity Platform, which provides real-time, automated verification for both individuals (KYC) and businesses (KYB). Our partnership and solution offering with Data Zoo is key to Ping Identity’s vision of verified trust.”

About Data Zoo
Data Zoo is the trusted data layer for global identity verification. Our single integration provides businesses with secure access to high-quality, privacy-first data from authoritative sources in over 60 countries, including registries, credit bureaus, telcos, and government databases. Through intelligent sequencing and pre-validation, Data Zoo delivers faster, more accurate verification while reducing costs and complexity. Leading enterprises and identity providers trust our data and expertise to strengthen compliance, prevent fraud, and onboard more customers globally.

Data Zoo Media Contact:
Emma Murphy
Marketing & Communications Director
emma.murphy@datazoo.com 

About Ping Identity
At Ping, we make it possible to trust every digital moment—moments with customers, employees, partners, and non-human identities. Whether you’re securing millions of users, fighting sophisticated fraud, simplifying third-party access, or embracing passwordless experiences and verifiable credentials, establishing trust shouldn’t slow you down. Our enterprise-grade identity platform is built for scale, speed, and flexibility—and works seamlessly with your existing tech stack across cloud, hybrid, and on-prem. We help innovators like you accelerate growth and confidently leverage AI—making life easier for your developers, users, IT teams, and partners. With Ping, all your digital experiences start with trust. Learn more at pingidentity.com.

Ping Identity Media Relations
press@pingidentity.com